Tirzepatide ���子背景与靶点 — 2026 Update

By Editorial Desk · published 2025-10-17 · last reviewed 2025-11-16 · Wiki

Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

Dual Incretin Receptor Pharmacology

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Related pages on this site

• Simple trends
• Connected notes
• Measured briefing
• Reliable guide
• Technical collection
• Adaptive dataset
• Material primer
• Smart comparison

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Molecular Background and Receptor Pharmacology

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

Supporting material

=== Arms Offences Act === The Arms Offences Act regulates criminal offences dealing with firearms and weapons. Any person who uses or attempts to use arms (Section 4) can face execution, as well as any person who uses or attempts to use arms to commit scheduled offences (Section 4A). These scheduled offences are being a member of an unlawful assembly; rioting; certain offences against the person; abduction or kidnapping; extortion; burglary; robbery; preventing or resisting arrest; vandalism; mischief. Any person who is an accomplice (Section 5) to a person convicted of arms use during a scheduled offence can likewise be hanged. Trafficking in arms (Section 6) is a capital offence in Singapore. Under the Arms Offences Act, trafficking is defined as being in unlawful possession of more than two firearms. One notable case involving a conviction under this act was the murder of Lim Hock Soon, where Ang Soon Tong triad leader Tan Chor Jin used a Beretta pistol to fatally shoot Lim, a nightclub owner, to death after robbing him and his family of their valuables. Tan was initially charged under the Penal Code for murder but the charge was later amended into one of illegal discharge of firearms under the Arms Offences Act. Tan was eventually convicted and executed by hanging under this Act on 9 January 2009.

== Relationship with humans == Prior to the 1970s, the white shark as a species was known mostly to biologists and fishermen. The 1971 documentary Blue Water, White Death is credited with introducing the species to the public. Its popularity grew further following Peter Benchley's 1974 novel Jaws, and its 1975 film adaptation, directed by Steven Spielberg. Both works established the species' image as a dangerous man-eater, a characterization Benchley later regretted. Compared to other fish, the white shark was not a significant commercial species. Although its meat was considered edible, the difficulty of capture made commercial fishing impractical. However, its size and reputation made it a popular target for sport fishing. Typically, sharks were lured with chum (ground bait) before being presented with a hook. Port Lincoln, South Australia, became a hub for white shark fishing in the 1950s. In 1959, a fisherman named Alf Dean caught a 1,208 kg (2,663 lb) shark there, setting the record for the largest fish caught by rod and reel. A larger shark caught in Streaky Bay was later disqualified due to the bait used.

Loss of NMNAT2 initiates Wallerian degeneration. By contrast, NMNAT2 enhancement opposes the actions of SARM1 which would lead to axon degeneration, but this effect is not due to preventing SARM1 depletion of NAD+. Mice lacking NMNAT2 die before birth, but are completely rescued by SARM1 deletion. Activation of NMNAT2 by Sirtuin 3 (SIRT3) may be a means of inhibiting axon degeneration and dysfunction. The catechin epigallocatechin gallate (EGCG) found in tea can activate NMNAT2 by more than 100%.

=== Concatemerization === The concatemerization process generates libraries of concatamers for the ELPs. Concatamers are oligomeric products of ligating a single gene with itself. This will result in repeat segments of a gene, all of which can be transcribed and translated immediately to produce the ELP of interest. A major problem with this synthetic route is that the number of gene repeat segments ligated together to form the concatamer cannot be controlled, leading to ELPs of different sizes, from which the ELP of a desired size must be isolated.

In 1981 Channon left Guy's Hospital to continue his work with Drs Martin Hartog and Richard Paisey at the Bristol Royal Infirmary. Channon then developed the miniature Portaject device. Unlike the Multiject the Portaject is designed to be worn. It has the capacity for sufficient insulin for 24 hours (at the time insulin had to be refrigerated; at room or body temperature it would become unusable after 24 hours). Channon self-funded the design and fabrication work through his company Channon Medical Ltd. He filed a patent for the Portaject in 1988 but subsequently withdrew the application, choosing instead to donate his research to the field. Clinical trials at the BRI were supported by a small grant of £4,500 from the National Medical Research fund. Dr Hartog attests that "Portaject was the first device that allowed convenient repeated subcutaneous injections of insulin and led to the Novopen. Administration of insulin in this way resulted in a much improved control of the patient's diabetes and, consequently, to a considerably improved prognosis overall". Dr Paisey recalls that clinical trials were conducted with 20 patients and that "one of them continued for 20 years with the same device and achieved good glycemic control. He also designed and manufactured a belt to house the pump". Another long term user, Stephen Dixon, wrote to Channon "Thanks so much for doing what you did. You truly helped transform millions of lives, including mine". In 1989 Channon developed a simple device for protecting, lubricating and sterilizing a hypodermic needle.

Sources: en.wikipedia.org

Notes from published material

M791 armor-piercing discarding sabot with tracer The APDS-T penetrates lightly armored vehicles, self-propelled artillery, and aerial targets such as helicopters and various slow-moving, fixed-wing aircraft. Reported velocity of 1,345 m/sec. M792 high explosive incendiary with tracer and self destruct The HEI-T can destroy unarmored vehicles and helicopters and suppress anti-tank missile positions and enemy squads out to a maximum effective range of 2,200 meters. Uses the M758 fuse, reported velocity of 1,100 m/sec. M793 target practice with tracer The TP-T cartridge is a fixed-type, percussion-primed training round that matches the high explosive incendiary with tracer (HEI-T M792) round ballistically. The TP-T's tracer is visible out to 2,000 meters, however, the round has a maximum effective range (accuracy-limited) of 1,600 meters. Reported velocity of 1,100 m/sec. M910 target practice discarding sabot with tracer The TPDS-T replicates the flight pattern of the M791 armor piercing discarding sabot with tracer (APDS-T) round. The TPDS-T allows units to realistically practice sabot engagements. Reported velocity of 1,515 m/sec. MK210 high explosive incendiary with tracer Used by the U.S. Navy in their Mk38 naval weapon system. M919 armor-piercing, fin-stabilized discarding sabot with tracer. The APFSDS-T round penetrates lightly armored vehicles, self-propelled artillery, and aerial targets, which include helicopters and slow-moving fixed-wing aircraft. The dart is made of depleted uranium.

Early lichenologists later reclassified the species in different genera. For instance, Erik Acharius (1803) referred to it as Parmelia parietina in his work Methodus, and Giuseppe De Notaris (1847) listed it as Physcia parietina. Johannes M. Norman (1852) treated it under Teloschistes (a related genus of orange-colored lichens), calling it Teloschistes parietinus. The modern genus Xanthoria was established by Theodor Fries. In 1860, he formally recombined the species as Xanthoria parietina. In his treatment, Fries recognized a distinct form, which he called Xanthoria aureola, distinguishing it from the more common form of X. parietina. He described aureola as a primary and fundamental form of the species, particularly prevalent in Arctic regions, differing from typical X. parietina in its color, rigid thallus, and preference for exposed habitats. Fries also cited Acharius, who considered aureola an intermediate between Xanthoria elegans (now Rusavskia elegans) and X. parietina. These distinctions may have contributed to later taxonomic interpretations that recognized Xanthoria aureola as a separate species. Xanthoria parietina is the type species of the genus Xanthoria. The designated lectotype for Xanthoria parietina is the illustration cited by Linnaeus from Dillenius (1742). Due to its reclassification across different genera, Xanthoria parietina has accumulated many synonyms in the literature. In addition to generic transfers, various infraspecific taxa (forms, varieties, or subspecies) have been described, particularly regarding morphological variants.

=== Gene delivery === While gene therapy has gained significant attention from the medical community, especially for cancer therapy, a lack of safe and efficient gene delivery vectors has become a bottleneck to clinical translation. While viral vectors demonstrate high transfection efficiency and protect delivered genes, there are safety concerns associated with immune responses to the virus. Many nonviral vectors have been proposed, especially cationic lipids and polymers. However, these demonstrate low transfection efficiency compared to viruses. Therefore, RGD has been coupled to nonviral vectors to target delivery of genetic material to the desired cells, thereby increasing transfection efficiency.

A notable and unusual building in the area is the so-called "Fetta di Polenta" (lit. 'polenta slice'), formerly known as Casa Scaccabarozzi. This building is where Corso San Maurizio meets Via Giulia di Barolo, and it is one of the most peculiar examples of Turin architecture: a thin trapezoid 27 m (89 ft) wide on Via Giulia Di Barolo, 5 m (16 ft) on Corso San Maurizio and just 0.70 m (2 ft 4 in) wide on the opposite end. It was designed in 1840 by Alessandro Antonelli for his wife, Francesca Scaccabarozzi. The curious name comes from the shape of the palace, which resembles a "slice of polenta", and also because it is painted with an ochre colour. In the surroundings, in Via Vanchiglia 8 (although in downtown and not really in Vanchiglia anymore), there is another trapezoid house, albeit with less extreme design: similarly, this building is nicknamed "Fetta di Formaggio" (lit. 'cheese slice'), built in 1832 for the rich Marchese Birago di Vische by the architect Antonio Talentino. Other notable buildings are the town public baths, eclectic building built in 1905 (Corso Regina Margherita crossing Via Vanchiglia), and theTeatro della Caduta theatre, opened in 2003 in Via Michele Buniva 23, which with its 45 seats is the smallest theatre in Turin and among the smallest theatres in Europe. In Corso Regina Margherita, another notable building is the former Opera pia Reynero, a charitable organisation. The building was built in 1892.

== Mutations == Mutations in genes encoding uniporters lead to dysfunctional transporter proteins being formed. This loss of function in uniporters causes disruption in cellular function which leads to various diseases and disorders.

Sources: en.wikipedia.org

Frequently asked questions